MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share
MPLT•Closing and use of proceeds
Closing is expected on Aug. 14, 2026, subject to customary conditions. MapLight said it will file a resale registration statement with the SEC.
Proceeds are earmarked for ML-007C-MA development, with cash runway projected through 2028 including PIPE net proceeds.
MapLight Therapeutics prices $150 million PIPE
MapLight Therapeutics priced a USD 150 million PIPE of unregistered equity securities, led by new and existing institutional investors.
The sale covers 9,197,887 common shares at USD 11.38, with pre-funded warrants for up to 3,983,168 shares at USD 11.38. The pre-funded warrants carry a USD 0.0001 exercise price, are immediately exercisable, and do not expire.
